Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

On to the clinic
February 2020
SHARING OPTIONS:

GROSSE POINTE FARMS, Mich.—SciTech Development's Investigational New Drug (IND) application for ST-001 nanoFenretinide was accepted by the U.S. Food and Drug Administration, SciTech announced recently. This clears ST-001 nanoFenretinide, an experimental treatment for T-cell non-Hodgkin's lymphoma (NHL), to enter clinical trials. The first study will be conducted at the Rush University Medical Center, and will consist of patients with relapsed/refractory T-cell NHL, with a scheduled start date of mid-2020. ST-001 nanoFenretinide features a nanoparticle suspension to allow for intravenous administration.
 
Earle Holsapple, president of SciTech Development, commented in part that “FDA approval of our IND for ST-001 is a significant milestone in the development of our SciTech Drug Delivery Vehicle (SDV) program.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.